Logo

Theramex Collaborates with Enzene for the Registration and Commercialization of Biosimilar Denosumab

Share this

Theramex Collaborates with Enzene for the Registration and Commercialization of Biosimilar Denosumab

Shots:

  • The companies entered into an agreement to register and commercialize denosumab (biosimilar referencing Prolia) for use in the EU- the UK- Switzerland- and Australia
  • Enzene will exclusively supply the finished product to Theramex for the duration of the agreement
  • Denosumab (SC- once every 6mos.) is a human mAb (IgG2) that targets and binds with high affinity and specificity to RANKL- preventing activation of its receptor- RANK- on the surface of osteoclast precursors and osteoclasts

  | Ref: Theramex | Image: Theramex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions